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Introduction: Non-invasive ventilation (NIV) is recommended for treatment of acute hypercapnic 
respiratory failure (AHRF) refractory to medical management in patients with acute exacerbations of 
COPD. National UK audit data suggests that mortality rates are rising in COPD patients treated with 
NIV.
Objective: To investigate temporal trends in in-hospital mortality in COPD patients undergoing a first 
episode of ward-based NIV for AHRF.
Methods: Retrospective study of hospitalised COPD patients treated with a first episode of ward-
based NIV at a large UK teaching hospital between 2004 to 2017. Patients were split into two cohorts 
based on year of admission, 2004-2010 (Cohort 1) and 2013-2017 (Cohort 2), to facilitate comparison 
of patient characteristics and in-hospital mortality.
Results: In total, 547 unique patients were studied. There was no difference in in-hospital mortality 
rate between the time periods studied (17.6% vs. 20.5%, p=0.378).  In Cohort 2 there were more 
females, a higher rate of co-morbid bronchiectasis and a higher rate of pneumonia on admission , 
higher rate of co-morbid bronchiectasisand more severe acidosis, hypercapnia and hypoxia. , More 
patients in Cohort 2 had greater proportion of patients with NIV as the ceiling of treatment. Patients in 
Cohort 2 experienced a, longer time from AHRF diagnosis to application of NIV, higher maximum 
inspiratory positive airway pressure, lower maximum oxygen and, shorter duration of NIV. ,Finally, 
patients in Cohort 2 experienced a  shorter hospital length of stay (LOS), with no differences observed 
in rate of transfer to critical care or intubation. in hospital and more severe acidosis, hypercapnia and 
hypoxia.
Conclusion: In-hospital mortality remained stable and LOS decreased over time, despite greater 
comorbidity and more severe AHRF in COPD patients treated for the first time with ward-based NIV 
for AHRF. This study highlights a need for evaluation of factors influencing clinician decisions to 
manage patients with concomitant pneumonia and severe AHRF with ward-based NIV.
Key words: chronic obstructive pulmonary disease; acute exacerbation; acute hypercapnic 
respiratory failure; non-invasive ventilation; trends; survival; mortality.





























































































































Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide [1]. A 
significant increase in the rate of acute exacerbations of COPD (AECOPD) has been observed in 
England with many patients requiring hospitalisation [2]. Acute hypercapnic respiratory failure (AHRF) 
occurs in around 20% of hospitalised patients with AECOPD and is associated with increased 
mortality [3,4]. Non-invasive ventilation (NIV) is recommended for the treatment of AHRF refractory to 
optimal medical management [5,6]. The survival benefits associated with NIV seen in ‘real life’ data 
have been smaller than the original randomised controlled trials and the literature describing long-
term outcomes is limited [7,8]. This study aimed to investigate temporal trends in in-hospital mortality 
in COPD patients treated with ward-based NIV for AHRF. 
Methods:
Hospitalised COPD patients undergoing a first episode of ward-based NIV for AHRF at a large 
teaching hospital in the West Midlands (UK) were prospectively enrolled into the NIV department 
registry between July 2004 to November 2017. Patients were selected for ward-based NIV as per 
Trust protocol (Figure 1) and NIV was delivered on an 11 bed, respiratory physiotherapist lead unit 
according to national guidelines. Nurses and physiotherapists underwent protocolised training to 
deliver ward-based NIV. The nurse-to-patient ratio was determined using an acuity-based nursing 
staffing level scoring system which calculates the number of nurses needed to staff the NIV unit safely 
(2-4 nurses). NIV was delivered continuously and patients were weaned as per Trust protocol. Pre-
NIV arterial blood gas results were entered prospectively into the registry by NIV physiotherapists. 
Clinical diagnoses of COPD were confirmed with spirometry demonstrating an FEV1/FVC ratio <0.7. 
In patients without spirometry, discharge letters, respiratory clinic letters, chest x-rays and computed 
tomography (CT) findings were also reviewed to verify clinical diagnoses. Admission chest x-ray 
reports were reviewed to confirm or refute diagnoses of pneumonia. CT scans were reviewed for 
evidence of bronchiectasis. Data were analysed in STATA version 15 (StataCorp, Texas, USA). The 
cohort was split into two groups based on year of admission, 2004-2010 and 2013-2017, to facilitate 
comparison of patient characteristics and in-hospital mortality. The years 2011-2012 were excluded 
due to incomplete data capture during this time. 































































In total, 547 unique patients were studied. Patient characteristics are summarised in Table 1. Overall, 
104 patients (19%) died in-hospital during their first episode of ward-based NIV for AHRF. There was 
no statistically significant difference in rate of in-hospital mortality between Cohort 1 and Cohort 2. In 
the Cohort 2 there were more females, a higher rate of pneumonia on admission, higher rate of co-
morbid bronchiectasis, higher FEV1, greater proportion of patients with NIV as the ceiling of treatment, 
longer time from respiratory failure diagnosis to application of NIV, higher maximum IPAP, lower 
maximum oxygen, shorter duration of NIV, shorter length of stay in hospital and more severe acidosis, 
hypercapnia and hypoxia.
Discussion:
There was no evidence to support a difference in in-hospital mortality between the time periods 
studied. Our in-hospital mortality was higher than the original randomised controlled trials advocating 
the use of NIV in AECOPD however it was lower the in-hospital mortality rate of 25.1% reported by 
the recent National Confidential Enquiry into Patient Outcomes and Death (NCEPOD) [7,8].
Despite the stability of in-hospital mortality over time, we found that patients in Cohort 2 had more 
severe acidosis, hypercapnia and hypoxia. In keeping with data from the NCEPOD report, our 
findings may reflect increased confidence and a willingness to manage patients with worse blood gas 
results on the ward, rather than transferring them to critical care, this requires further study [8,9]. 
Interestingly, despite guidelines recommending against the use of ward-based NIV in patients with 
pneumonia [5], we found that more patients in the Cohort 2 had concomitant pneumonia on admission 
chest x-ray. This may, in part, be due to a greater proportion of patients in Cohort 2 having NIV as 
their ceiling of treatment. However, this may also suggest that clinicians are choosing to utilise ward-
based NIV more frequently in COPD patients with AHRF and pneumonia, rather than escalating to 
critical care. We cannot rule out the possibility that patients had been escalated to critical care and 
subsequently had been deemed unsuitable for transfer by the assessing clinicians. A prospective 
study is required which adequately captures data regarding if patients had been escalated to critical 
care and if ward-based NIV was placed as the ceiling of treatment. 






























































We observed a slightly longer time difference between diagnosis of AHRF and application of NIV in 
the Cohort 2. The increasing frequency of emergency department attendances and emergency 
hospital admissions in England may result in slower intra-hospital transfer times and a longer time to 
initiate NIV. This study highlights a possible need for quality improvement to meet the recently 
published BTS ‘Quality Standards for acute non-invasive ventilation in adults’ statement: “Patients 
who meet evidence-based criteria for acute NIV should start NIV within 60min of the blood gas result 
associated with the clinical decision to provide NIV and within 120min of hospital arrival for patients 
who present acutely.” [10]. The observation that there were fewer males in Cohort 2 was unexpected 
and may reflect an increasing prevalence of COPD in females in England [11]. 
Patients in Cohort 2 received a higher maximum IPAP and a lower maximum oxygen; this likely 
reflects greater understanding of acute NIV and the evidence-base for higher pressures and 
controlled oxygen therapy in AECOPD [5]. We observed a higher rate of bronchiectasis in Cohort 2 
which we suspect may reflect an increase in diagnostic CT scanning, rather than increased incidence. 
Whilst we observed a higher FEV1 % predicted in Cohort 2 (35% vs 32%) this is not considered a 
clinically important difference and both cohorts demonstrated severe airflow obstruction. Finally, we 
observed a shorter duration of NIV treatment and a shorter length of hospital stay in Cohort 2, of 
approximately 1 day and 2 days respectively. The evolution of community and integrated care in 
COPD along with increased demand for inpatient beds in the UK may explain the bed occupancy 
reduction, however the reasons for these findings are likely to be multifactorial and require further 
investigation. Increased confidence acquired over the past decade in the delivery of ward-based NIV 
in AECOPD may have contributed to the shorter duration of NIV treatment in patients in Cohort 2. 
Additionally, increased provision of domiciliary NIV for COPD patients with hypercapnic respiratory 
failure may facilitate faster weaning from acute NIV and discharge from hospital.
Key strengths of this study include the large cohort size, long observation period and reliability of 
COPD diagnoses. Limitations include the single centre, retrospective design and uncontrolled 
observational cohort nature of this study. 
In summary, in-hospital mortality remained stable over time in COPD patients treated for the first time 
with ward-based NIV for AHRF. Patients in Cohort 2 had more severe AHRF, a higher rate of 
pneumonia and a shorter hospital stay. This study highlights a need for further evaluation of factors 






























































influencing clinician decisions to manage patients with concomitant pneumonia and severe AHRF with 
ward-based NIV rather than managing them in critical care.
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Table 1: Participant characteristics for the whole cohort and for patients split based on year of 
hospital admission – Cohort 1 (2004-2010) and Cohort 2 (2013-2017).
Median [IQR] or n (%)





Age (years) 70.6 [63.8-78.1] 72.1 [64.2-78.8] 69.9 [63.7-76.9] 0.1140
Male gender 245 (44.8) 139 (49.8) 106 (39.6) 0.016
Pneumonia on admission 143 (27.7) 47 (18.9) 96 (35.8) <0.0001
Bronchiectasis 104 (26.4) 36 (18.4) 68 (34.3) <0.0001
FEV1 (litres) 0.71 [0.54-0.96] 0.66 [0.52-0.89] 0.77 [0.57-1.05] 0.0033
FEV1 % predicted 34 [26-43] 32 [24-39] 35 [27-47] 0.0042
NIV ceiling of treatment 286 (52.3) 108 (38.7) 178 (66.4) <0.0001
Pre-NIV pH 7.27 [7.21-7.3] 7.28 [7.23-7.31] 7.25 [7.2-7.29] 0.0002
Pre-NIV pCO2 (kPa) 9.91 [8.43-11.50] 9.36 [8.16-11] 10.34 [8.89-11.8] 0.0002
Pre-NIV pO2 (kPa) 7.83 [6.73-9.49] 9.06 [7.34-11.05] 7.22 [6.27-7.96] 0.0001
RF to NIV (hours) 1.83 [1-3.67] 1.63 [1-3.32] 2.08 [1.23-4.03] 0.0016
Duration of NIV (days) 5.07 [3.04-7.1] 5.07 [3.04-8.12] 4.06 [2.03-7.10] 0.006
Maximum IPAP (cmH2O) 16 [14-20] 15 [12-18] 18 [15-21] <0.0001
Maximum EPAP (cmH2O) 5 [4-6] 5 [4-5] 5 [4-6] <0.0001
Maximum oxygen (L/min) 5 [3-10] 8 [5-13] 4 [2-6] <0.0001
Transferred to ITU 17 (3.1) 5 (1.8) 12 (4.5) 0.07
Intubated 10 (1.8) 5 (1.8) 5 (1.9) 0.953
In-hospital mortality 104 (19) 49 (17.6) 55 (20.5) 0.378
Time to in-hospital mortality (days) 9.13 [5.07-14.20] 9.13 [ 6.09-19.28] 9.13 [5.07-12.18] 0.5398
Length of stay (days)† 10.15 [6.09-17.25] 11.16 [7.10-19.28] 9.13 [6.09-13.19] 0.0001
Abbreviations: CT, computed tomography; FEV1, forced expiratory volume in one second; NIV, non-invasive 
ventilation; RF to NIV, time from diagnosis of respiratory failure to application of NIV; IPAP, inspiratory positive 
airway pressure; EPAP, expiratory positive airway pressure; ITU, intensive care unit. †Length of stay calculated 
for patients who survived to hospital discharge (n=443). Non-parametric data expressed as median [inter-quartile 
range] and analysed using the Wilcoxon rank-sum test. Categorical data expressed as number (percentage) and 
analysed using the Chi-squared test. A p-value <0.05 was considered statistically significant.
Figure Legends
Figure 1. Inpatient NIV referral pathway.































































Figure 1. Inpatient NIV referral pathway. 
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